Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Shell
SHEL
|
+$1.04B |
| 2 |
State Street SPDR Portfolio Long Term Treasury ETF
SPTL
|
+$896M |
| 3 |
BHP
BHP
|
+$620M |
| 4 |
Amazon
AMZN
|
+$608M |
| 5 |
NVIDIA
NVDA
|
+$555M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RDS.A
Royal Dutch Shell PLC ADS Class A
RDS.A
|
+$813M |
| 2 |
Walt Disney
DIS
|
+$667M |
| 3 |
Intel
INTC
|
+$658M |
| 4 |
UnitedHealth
UNH
|
+$649M |
| 5 |
Cisco
CSCO
|
+$646M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.43% |
| 2 | Healthcare | 10.84% |
| 3 | Financials | 9.96% |
| 4 | Consumer Discretionary | 9.46% |
| 5 | Communication Services | 7.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GHL
376
DELISTED
Greenhill & Co., Inc.
GHL
| $7.13M | ﹤0.01% |
461,098
| – | – |
|
377
Neurocrine Biosciences
NBIX
$16.6B
| $7M | ﹤0.01% |
74,656
+9
| +0% | +$763 |
|
|
CHX
378
DELISTED
ChampionX
CHX
| $6.96M | ﹤0.01% |
284,387
+372
| +0.1% | +$8.61K |
|
379
Evercore
EVR
$11.8B
| $6.93M | ﹤0.01% |
62,297
+2,273
| +4% | +$280K |
|
380
Tetra Tech
TTEK
$9.07B
| $6.87M | ﹤0.01% |
208,255
+290
| +0.1% | +$8.92K |
|
381
Roper Technologies
ROP
$39.8B
| $6.86M | ﹤0.01% |
14,530
+1,626
| +13% | +$732K |
|
382
CVS Health
CVS
$122B
| $6.86M | ﹤0.01% |
67,780
+5,141
| +8% | +$540K |
|
383
Factset
FDS
$10.2B
| $6.84M | ﹤0.01% |
15,760
+199
| +1% | +$84K |
|
384
Vanguard FTSE Emerging Markets ETF
VWO
$124B
| $6.77M | ﹤0.01% |
146,743
+12,999
| +10% | +$625K |
|
385
First Interstate BancSystem
FIBK
$3.58B
| $6.73M | ﹤0.01% |
183,008
+61,008
| +50% | +$2.4M |
|
|
MDC
386
DELISTED
M.D.C. Holdings, Inc.
MDC
| $6.68M | ﹤0.01% |
176,621
+4,240
| +2% | +$194K |
|
387
Vanguard Morningstar Growth ETF
VUG
$231B
| $6.67M | ﹤0.01% |
139,056
+70,746
| +104% | +$3.35M |
|
|
ANSS
388
DELISTED
Ansys
ANSS
| $6.58M | ﹤0.01% |
20,705
+1,488
| +8% | +$486K |
|
|
FBGX
389
DELISTED
UBS AG FI Enhanced Large Cap Growth ETN
FBGX
| $6.58M | ﹤0.01% |
9,228
-156
| -2% | -$106K |
|
390
Xylem
XYL
$28.1B
| $6.46M | ﹤0.01% |
75,735
+8,907
| +13% | +$853K |
|
|
PCH
391
DELISTED
PotlatchDeltic
PCH
| $6.43M | ﹤0.01% |
121,971
+1,187
| +1% | +$64.8K |
|
392
Vertex Pharmaceuticals
VRTX
$126B
| $6.42M | ﹤0.01% |
24,584
-687
| -3% | -$163K |
|
393
Globe Life
GL
$14.3B
| $6.41M | ﹤0.01% |
63,750
-85
| -0.1% | -$8.62K |
|
394
Vanguard Total World Stock ETF
VT
$79.8B
| $6.33M | ﹤0.01% |
62,483
+4,864
| +8% | +$493K |
|
|
SFBS
395
ServisFirst Bancshares
SFBS
$4.86B
| $6.29M | ﹤0.01% |
66,030
+7,251
| +12% | +$633K |
|
396
Acuity Brands
AYI
$10.8B
| $6.19M | ﹤0.01% |
32,678
-1,716
| -5% | -$330K |
|
|
COWN
397
DELISTED
Cowen Inc. Class A Common Stock
COWN
| $6.17M | ﹤0.01% |
227,851
+72,811
| +47% | +$2.22M |
|
398
8x8 Inc
EGHT
$332M
| $5.99M | ﹤0.01% |
475,814
+108,984
| +30% | +$1.51M |
|
|
SPR
399
DELISTED
Spirit AeroSystems
SPR
| $5.97M | ﹤0.01% |
122,107
+2,306
| +2% | +$108K |
|
400
Clorox
CLX
$12.7B
| $5.88M | ﹤0.01% |
42,291
+167
| +0.4% | +$25.6K |
|
Similar funds
Ken Fisher's Q1 2022 Portfolio in Review
As of Q1 2022, Ken Fisher held 1,181 positions worth $169B, down 5.1% from $179B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Fisher deployed $5.41B of net new capital in Q1 2022, opening 114 new positions and adding to 450 existing holdings. Its largest new stake was Shell: 19,596,216 shares worth $1.08B.
By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 30% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Walt Disney, an estimated $667M trimmed.
- Ken Fisher's largest Q1 2022 buy was Shell: 19,596,216 shares worth $1.08B.
- Ken Fisher added most to State Street SPDR Portfolio Long Term Treasury ETF in Q1 2022, an estimated $896M increase.
- Ken Fisher's biggest Q1 2022 reduction was Walt Disney, cutting an estimated $667M.
- Ken Fisher fully exited Royal Dutch Shell PLC ADS Class A in Q1 2022, selling an estimated $813M.
- Ken Fisher's ten largest holdings make up 31% of its $169B portfolio in Q1 2022.
- Ken Fisher opened 114 new positions and closed 95 in Q1 2022.
- Ken Fisher's portfolio value fell 5.1% quarter-over-quarter to $169B.
Based on Fisher Asset Management's 13F filing for Q1 2022, filed 5 May 2022.